Table 2.
Evolution of organ involvement among the 30 patients who presented an active sarcoidosis in adulthood.
| First Presentation * | Adulthood ** | p | |
|---|---|---|---|
| Organ involvement, median, (Q1–Q3) | 4 (2.7–4) | 1.5 (1–2) | <0.0001 1 |
| Lung, n (%) | 27 (90%) | 14 (47%) | 0.0006 2 |
| Eye, n (%) | 15 (50%) | 11 (36.6%) | ns 2 |
| Kidney, n (%) | 4 (13.3%) | 2 (6.6%) | ns 2 |
| Liver, n (%) | 17 (56.3%) | 7 (23.3%) | 0.017 2 |
| Peripheral lymph node, n (%) | 13 (43%) | 3 (10%) | 0.007 2 |
| Joints, n (%) | 5 (17%) | 1 (3.3%) | ns 2 |
| Skin, n (%) | 5 (17%) | 3 (10%) | ns 2 |
| Spleen, n (%) | 6 (20%) | 1 (3.3%) | ns 2 |
| Central neurologic, n (%) | 3 (10%) | 3(10%) | ns 2 |
| General signs, n (%) | 11 (36.7%) | 2 (6.6%) | <0.05 2 |
| Fever, n (%) | 8 (26%) | 0 (0%) | 0.01 2 |
| Fatigue, n (%) | 11 (36%) | 2 (6.6%) | <0.002 2 |
* Assessment of organ involvement at the first pediatric evaluation. Q1: first quartile, Q3: third quartile. ** Assessment of organ involvement in adulthood defined as a relapse after the age of 18. 1: p value obtained by Wilcoxon matched pairs signed rank test, 2: p value obtained by Fisher’s exact test. ns: nonsignificant.